Therefore, during long-term endocrine resistance in HR+ BC, identifying a clinical target with both GPCR and ERα functions will facilitate our better exploration of the resistant mechanisms and present opportunities to develop more accurate drugs with greater efficacy and minimal adverse reactions. Here, ESR1 is linked to breast cancer.